英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
immunis查看　immunis　在百度字典中的解释百度英翻中〔查看〕
immunis查看　immunis　在Google字典中的解释Google英翻中〔查看〕
immunis查看　immunis　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Therapeutics targeting age-related disease - Immunis, Inc.
    Immunis is a clinical-stage biotechnology company targeting age-driven diseases to promote a healthier lifespan
  • Clinical Trials for Age-Related Muscle Atrophy - Immunis, Inc.
    Immunis developed an investigational therapeutic (IMM01-STEM) derived from the secreted factors of human stem cells and is testing its efficacy in reversing age-related muscle atrophy in elderly adults and canines
  • Multi-active Biologics for Immune and Age-related Diseases - Immunis, Inc.
    Our multi-active biologics can potentially benefit the immune system, thereby improving the outlook on age and immune-related diseases
  • Latest News about Immunis Investigational Secretome Treatment . . .
    Immunis Inc , a private biotechnology company developing a novel treatment for age and disease-related immune decline, announced today the peer-reviewed publication of a research study conducted by Professor Micah J Drummond at the University of Utah investigating the efficacy of Immunis’ immunomodulatory secretome product on aged skeletal
  • Immunis Successfully Completes its Phase 1 2a Clinical Trial Targeting . . .
    Immunis, Inc , a clinical-stage biotech developing novel, multi-active biologics for age and disease-related immune dysregulation, is proud to announce the successful completion of its Phase 1 2a clinical trial The clinical study investigated the safety, tolerability, and preliminary efficacy of Immunis’ investigational therapy, IMM01-STEM, in reversing muscle atrophy in elderly individuals
  • Immunis Licenses Treatment Candidate for Dyskinesia Associated with . . .
    Immunis, Inc , a clinical-stage biotech company targeting age-related diseases, today announced it has entered an exclusive licensing agreement with Toray to develop and commercialize a drug candidate for the treatment of dyskinesia associated with Parkinson’s disease
  • Immunis Announces Secretome Product for Muscle Atrophy
    Immunis, Inc , a private biotech company developing an innovative treatment for age and disease-related immune decline, announces its first-in-human injection of IMM01-STEM for its STEM-MYO Phase 1 2a clinical trial The goal is to assess the safety and tolerability of Immunis’ investigational stem cell secretome product, IMM01-STEM, in patients with muscle atrophy related to knee
  • Immunis completed a Phase 1 2a clinical trial for its multi-active therapy
    Immunis successfully completed a Phase 1 2a clinical trial for its multi-active therapy The trial tested the safety, tolerability and preliminary efficacy of IMM01-STEM in elderly individuals with muscle atrophy associated with knee osteoarthritis We are excited to share the highlights from our trial
  • Media - Immunis, Inc.
    Immunis is often highlighted and honored by reputable scientific and business-oriented media outlets, and we've organized them in one place!





中文字典-英文字典  2005-2009